Significant advances in drugging difficult targets have been developed in academic and industrial research centers and have begun to be utilized in high-throughput screens towards validating efficacy and identifying functional phenotypes. The goal of our upcoming Symposium is to provide illustrations of novel classes of therapeutic agents that have been developed, showcasing screening methodology used to identify entry points into these challenging targets, and how these projects matured into clinical relevant agents.
“RAS: The Elephant in the Room of Cancer Therapy”— Garth Powis, Ph.D., Sanford Burnham Medical Research Institute
“Total Syntheses of Natural and Designed Molecules of Biological and Medical Importance” — K.C. Nicolaou, Ph.D., Rice University
Other speakers include:
Kevin Burgess, Ph.D., Texas A&M University
Kurt Deshayes, Ph.D., Genentech
Scott Gilbertson, Ph.D., University of Houston
Ami S. Lakdawala, Ph.D, GlaskoSmithKline
John MacMillan, Ph.D., University of Texas Southwestern
John McMurray, Ph.D., MD Anderson Cancer Center
K.C. Nicolaou, Ph.D., Rice University
Tamas Oravecz, Ph.D., Lexicon Pharmaceuticals
Dafydd Owen, Ph.D., Pfizer
Garth Powis, Ph.D., Sanford-Burnham Medical Research Institute
Jun Qi, Ph.D., Dana-Farber Cancer Institute
Robert Sims, Ph.D., Constellation Pharmaceuticals Inc.
Yongcheng Song, Ph.D., Baylor College of Medicine
Nicholas Terrett, Ph.D., Ensemble Therapeutics Corporation
Sharad Verma, Ph.D., GlaxoSmithKline
Xiang-Qun "Sean" Xie, Ph.D., MBA, University of Pittsburgh
Nick joined Ensemble Therapeutics as the Chief Scientific Officer in May of 2006. In his role as CSO, Nick heads up our drug discovery program investigating the rapid synthesis of macrocycles using DNA-Programmed Chemistry, as drug candidates for disease relevant protein-protein and protease targets.
Nick has a B.A. and Ph.D. in Natural Sciences from Cambridge University.
Agilent Technologies offers a wide array of solutions for diverse research interests including genomics, proteomics, drug discovery, combichem and ADME/Tox in their Bio-Analytical Portfolio. Agilent Automation has a broad portfolio for sample preparation including the AssayMap Bravo for peptide sample prep using microchromatography cartridges, the combination of the Bravo and BenchBot for SISCAPA assays and the Encore Multispan liquid handling system for off deck integration and fully automated workflows. For more information, see attached PDF (Agilent Tech) and/or contact Kenda Evans.
Eurofins Cerep-Panlabs is a pre-clinical services CRO performing testing to characterize and de-risk your potential drug candidates. The assays contained and data generated by our cost-effective packages and potential add-ons help our clients characterize and better understand their candidate(s). In addition, they also provide the type of information that potential partners or investors request as part of the due diligence that is performed prior to making partnering or investment decisions. For more information, see the attached (Drug Candidate Assessment Package), or email Judy Winslow.
BioTek Instruments, Inc., is a global leader in the development, manufacture and sale of microplate instrumentation and software used to aid in the advancement of life science research and to facilitate the drug discovery process. Cytation™ 3 is a cell imaging multi-mode microplate reader that combines automated digital microscopy and conventional microplate detection. This patent pending design provides rich phenotypic cellular information with well-based intensity data. For more information, see the attached PDF (Cytation3 BioTek) and/or contact: David Kurtz.
ForteBio develops analytical systems that enable real-time analysis of biomolecular interactions (protein quantification and characterization of protein-protein interactions, etc.) in micro-volume sample sizes, providing information on affinity, kinetics, and concentration. The ForteBioOctet Platform is a label-free, real-time platform for small molecular analysis and screening. See the attached PDF (ForteBioOctet Small Molecules) and/or contact Matthew Malehorn.
Greiner Bio-One manufactures products for cell cultivation and analysis, microplates for high throughput / high content screening to enable industry and research the most rapid and efficient drug discovery, a complete line of dependable ready-to-use general labware tools used in laboratories everywhere, and innovative genotyping biochip technologies to detect gene defects and identify infectious agents. Greiner Bio-One offers a comprehensive range of state-of-the-art solutions for large genomic biorepository storage in 48 and 96 way Datamatrix Tube formats, compatible with automated laboratory handling. The attached PDF (Greiner Bio-One Biobanking Presentation) describes product development and design to overcome existing significant challenges for secure integrity and identity of long-term specimen or sample storage. Please contact Kim Brath for further information.
The Thermo Scientific brand encompasses a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Among many drug discovery services available at Thermo Scientific, the Maybridge portfolio offers a comprehensive range of chemistry products and services tailored to the drug discovery and biotechnology sector. The portfolio is driven by a keen understanding of the needs of the medicinal chemist and is designed to expedite the drug discovery process. See the attached PDF (ThermoFisher) and/or contact Rob Zambias.
PerkinElmer now offers a suite of enabling reagents and technologies to help further unravel the complex biology of epigenetics – shortening assay development time and accelerating drug discovery for key epigenetic targets. AlphaLISA for Epigenetics Research is a highly sensitive no wash detection for measuring peptide and protein modification by epigenetic enzymes. LANCE TR-FRET can be used to quantitate peptides, detecting specific methylation and acetylation states and is HTS friendly to design your own epigenetic screen strategy. See attached PDF (TxSACT PerkinElmer Epigenetics) or contact Brian Mercer.